Get started
Author

Katherine Payne

Observed names: K Payne, K. Payne, K. T. Payne, KATHERINE PAYNE, Payne, K, Payne, K., Payne, K.; id_orcid 0000-0002-3938-4350, Payne, Katherine, Payne, Katherine; id_orcid 0000-0002-3938-4350
Observed institutions: Guy's Hospital, University of Liverpool, Edge Hill University, Queen Mary University of London, University of Dundee, Pfizer (United States), King's College London, Manchester Academic Health Science Centre, University of Manchester, Sanquin, Manchester University NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, Royal College of Physicians, Manchester Collaborative Centre for Inflammation Research, University of Newcastle Australia, Vrije Universiteit Amsterdam, University of Sheffield, University of Edinburgh
ORCID: 0000-0002-3938-4350
Observed ORCID: 0000-0002-3938-4350
OpenAlex ID: A5014086012
Adapting clinical guidelines to take account of multimorbidity
2012 · B. Guthrie, K. Payne, et al. · BMJ · 554
Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines
2015 · S. Dumbreck, A. Flynn, et al. · BMJ · 348
PDF
Patient empowerment: The need to consider it as a measurable patient-reported outcome for chronic conditions
2012 · Marion McAllister, Graham Dunn, et al. · BMC Health Services Research · 302
PDF
The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review
2004 · Lee Hooper, Tamara J Brown, et al. · BMJ · 243
PDF
The Role of Qualitative Research Methods in Discrete Choice Experiments: A Systematic Review and Survey of Authors
2017 · Caroline Vass, Dan Rigby, et al. · Medical Decision Making · 221
PDF
Cost-effectiveness of cell salvage and alternative methods of minimising perioperative allogeneic blood transfusion: a systematic review and economic model
2006 · L Davies, T Brown, et al. · Health Technology Assessment · 217
PDF
HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis
2018 · Nick Dand, Michael Duckworth, et al. · Journal of Allergy and Clinical Immunology · 187
Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group
2012 · Eric Faulkner, Lieven Annemans, et al. · Value in Health · 169
PDF
Improvement in risk prediction, early detection and prevention of breast cancer in the NHS Breast Screening Programme and family history clinics: a dual cohort study
2016 · D Gareth Evans, Susan Astley, et al. · Programme Grants for Applied Research · 152
PDF
A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling
2006 · T Brown, L Hooper, et al. · Health Technology Assessment · 151
PDF
Economic methods for valuing the outcomes of genetic testing: beyond cost-effectiveness analysis
2008 · Scott D. Grosse, Sarah Wordsworth, et al. · Genetics in Medicine · 141
Valuing the Economic Benefits of Complex Interventions: When Maximising Health Is Not Sufficient
2012 · Katherine Payne, Marion McAllister, et al. · Health Economics · 137
Cost-effectiveness analyses of genetic and genomic diagnostic tests
2018 · Katherine Payne, Sean P. Gavan, et al. · Nature Reviews Genetics · 132
Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group
2020 · Eric Faulkner, Anke-Peggy Holtorf, et al. · Value in Health · 120
PDF
Patient Empowerment in Clinical Genetics Services
2008 · Marion McAllister, Katherine Payne, et al. · Journal of Health Psychology · 119
Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription
2007 · E. A. Fargher, K. Tricker, et al. · Journal of Clinical Pharmacy and Therapeutics · 118
Patients’ and Healthcare Professionals’ Views on Pharmacogenetic Testing and its Future Delivery in the NHS
2007 · Emily A Fargher, Charlotte Eddy, et al. · Pharmacogenomics · 108
Risk as an Attribute in Discrete Choice Experiments: A Systematic Review of the Literature
2014 · Mark Harrison, Dan Rigby, et al. · Patient · 104
The emotional effects of genetic diseases: Implications for clinical genetics
2007 · Marion McAllister, Linda Davies, et al. · American Journal of Medical Genetics Part A · 104
Outcome Measurement in Clinical Genetics Services: A Systematic Review of Validated Measures
2007 · Katherine Payne, Stuart Nicholls, et al. · Value in Health · 104
Concepts of ‘Personalization’ in Personalized Medicine: Implications for Economic Evaluation
2014 · Wolf Rogowski, Katherine Payne, et al. · PharmacoEconomics · 100
Current Methodological Issues in the Economic Assessment of Personalized Medicine
2013 · Lieven Annemans, Ken Redekop, et al. · Value in Health · 100
PDF
Are Patients with Intermediate TPMT Activity at Increased Risk of Myelosuppression When Taking Thiopurine Medications?
2010 · Jenny E Higgs, Katherine Payne, et al. · Pharmacogenomics · 98
The economic case for precision medicine
2018 · Sean P. Gavan, Alexander J. Thompson, et al. · Expert Review of Precision Medicine and Drug Development · 94
PDF
The impact of increasing workloads and role expansion on female community pharmacists in the United Kingdom
2007 · Wendy K. Gidman, Karen Hassell, et al. · Research in Social and Administrative Pharmacy · 91
Works count: 469
Citation count: 8,684
H-index: 50
I10-index: 152
Year
Topic
Type